Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, 8-week Comparing Safety and Tolerability of Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
Brief Summary: This is an 8-week, randomized, double blind, parallel group, 3-arm trial to compare 10 mg/day, 20 mg/day and 40 mg/day as starting doses of vilazodone following a switch from generic SSRIs and SNRIs. Vilazodone HCl under the trade name Viibryd™ is approved by the U.S. FDA for the treatment of major depressive disorder in adults. The purpose of this study is to evaluate the efficacy (how well the drug works), safety (the side effects), and tolerability (how well tolerated) of Vilazodone in preventing relapse or recurrence of depression. As vilazodone is not approved by the United States Food and Drug Administration (FDA) to prevent the recurrence of depression, for the purposes of this study it is considered investigational. The word "investigational" means that the study drug is still being tested in research studies and has not been approved for this use by the FDA.


Options:
A: Arm Label: lithium plus usual care; Type: EXPERIMENTAL; Interventions: Drug: lithium | Arm Label: usual care without lithium therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: usual care | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): lithium plus usual care | Intervention Type: DRUG; Name: usual care; Assigned to Arm(s): usual care without lithium therapy
B: Arm Label: Placebo + ADT Lead-in; Type: OTHER; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Arm Label: Placebo + ADT (Double-Blind); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Arm Label: Cariprazine + ADT (Double-Blind); Type: EXPERIMENTAL; Interventions: Drug: Cariprazine, Drug: Antidepressant Therapy (ADT) | Arm Label: Placebo + ADT (Continued Treatment); Type: OTHER; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine + ADT (Double-Blind) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + ADT (Continued Treatment), Placebo + ADT (Double-Blind), Placebo + ADT Lead-in | Intervention Type: DRUG; Name: Antidepressant Therapy (ADT); Assigned to Arm(s): Cariprazine + ADT (Double-Blind), Placebo + ADT (Continued Treatment), Placebo + ADT (Double-Blind), Placebo + ADT Lead-in
C: Arm Label: Vilazodone 10mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 20mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 40mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 10mg, Vilazodone 20mg, Vilazodone 40mg
D: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A

Answer: C